Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming Group N.V (PHAR) Other Accumulated Expenses: 2019-2021

Historic Other Accumulated Expenses for Pharming Group N.V (PHAR) over the last 3 years, with Dec 2021 value amounting to -$1.1 million.

  • Pharming Group N.V's Other Accumulated Expenses was N/A to -$1.7 million in Q2 2023 from the same period last year, while for Jun 2023 it was -$1.7 million, marking a year-over-year change of. This contributed to the annual value of -$1.1 million for FY2021, which is 67264.53% down from last year.
  • Per Pharming Group N.V's latest filing, its Other Accumulated Expenses stood at -$1.1 million for FY2021, which was down 67,264.53% from -$1,624 recorded in FY2020.
  • Pharming Group N.V's 5-year Other Accumulated Expenses high stood at -$1,624 for FY2020, and its period low was -$1.1 million during FY2021.
  • For the 3-year period, Pharming Group N.V's Other Accumulated Expenses averaged around -$379,875, with its median value being -$44,000 (2019).
  • Per our database at Business Quant, Pharming Group N.V's Other Accumulated Expenses surged by 96.31% in 2020 and then slumped by 67,264.53% in 2021.
  • Yearly analysis of 3 years shows Pharming Group N.V's Other Accumulated Expenses stood at -$44,000 in 2019, then spiked by 96.31% to -$1,624 in 2020, then crashed by 67,264.53% to -$1.1 million in 2021.